Boston Scientific Corp (BSX)

20.71
NYSE : Health Care
Prev Close 20.71
Day Low/High 0.00 / 0.00
52 Wk Low/High 15.67 / 24.79
Avg Volume 9.12M
Exchange NYSE
Shares Outstanding 1.36B
Market Cap 27.71B
EPS -0.20
P/E Ratio 407.00
Div & Yield N.A. (N.A)

Latest News

Boston Scientific Announces Agreement To Acquire Neovasc Advanced Biological Tissue Capabilities

Boston Scientific Announces Agreement To Acquire Neovasc Advanced Biological Tissue Capabilities

¿ $75M transaction enhances manufacturing expertise in structural heart

The Most Admired Corporate Dealmakers in a Record Year

The Most Admired Corporate Dealmakers in a Record Year

In a record year for acquisitions, 18 companies from across the spectrum were singled out by M&A professionals for doing deals that got results.

Boston Scientific Takes Over #76 Spot From Sherwin-Williams

Boston Scientific Takes Over #76 Spot From Sherwin-Williams

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Boston Scientific Corp. has taken over the #76 spot from Sherwin-Williams Co , according to ETF Channel.

Boston Scientific Closes EndoChoice Acquisition

Boston Scientific Closes EndoChoice Acquisition

Acquisition Expands Endoscopy Portfolio

Boston Scientific Announces Positive Results Of HeartLogic™ Heart Failure Diagnostic Service

Boston Scientific Announces Positive Results Of HeartLogic™ Heart Failure Diagnostic Service

Late-Breaking Trial Data Presented at AHA Scientific Sessions Demonstrate Success of Alert to Predict Worsening Heart Failure

Boston Scientific Acquires Resectr™ Tissue Resection Device From Distal Access, LLC

Boston Scientific Acquires Resectr™ Tissue Resection Device From Distal Access, LLC

Acquisition Advances Treatment Options for Women with Uterine Polyps

Boston Scientific Announces Acquisition Of The LumenR™ Tissue Retractor System

Boston Scientific Announces Acquisition Of The LumenR™ Tissue Retractor System

Technology to Improve Management of Gastrointestinal Diseases

Boston Scientific Announces Initial U.S. Commercial Performance Of The WATCHMAN™ Left Atrial Appendage Closure Device

Boston Scientific Announces Initial U.S. Commercial Performance Of The WATCHMAN™ Left Atrial Appendage Closure Device

Late-Breaking Trial Data Presented at TCT Scientific Sessions and Simultaneously Published in the Journal of the American College of Cardiology

Primary Endpoint From Study Of Drug Eluting Coronary Stent In Underserved Patient Populations Presented At TCT 2016

Primary Endpoint From Study Of Drug Eluting Coronary Stent In Underserved Patient Populations Presented At TCT 2016

The PLATINUM Diversity Study Provides Much Needed Data about Women and Minority Patients, Who are Under-represented in Cardiology Clinical Trials

'Mad Money' Lightning Round: Smith and Wesson Represents Value, Cramer Says

'Mad Money' Lightning Round: Smith and Wesson Represents Value, Cramer Says

Jim Cramer likes SWHC and BX, but not NAT and DBD.

Jim Cramer's 'Mad Money' Recap: How Powerful Are GE, Royal Dutch Shell and Occidental?

Jim Cramer's 'Mad Money' Recap: How Powerful Are GE, Royal Dutch Shell and Occidental?

Cramer previews important earnings reports scheduled for the coming week.

Boston Scientific Shares Flat Following Mixed Earnings Results

Boston Scientific Shares Flat Following Mixed Earnings Results

Boston Scientific reported earnings of $0.27, in-line with analyst expectations.

Boston Scientific (BSX) Stock Advances on Q3 Revenue Beat, Guidance

Boston Scientific (BSX) Stock Advances on Q3 Revenue Beat, Guidance

Boston Scientific (BSX) reported 2016 third-quarter revenue that exceeded analysts' expectations and raised its full-year revenue forecast.

Boston Scientific Remains Disciplined Buyer in Light of Large-scale Industry Consolidation

Boston Scientific Remains Disciplined Buyer in Light of Large-scale Industry Consolidation

The medical devices company is likely to stick to small- to mid- sized M&A unless it finds itself the target.

What to Look for When Boston Scientific (BSX) Reports Q3 Earnings

What to Look for When Boston Scientific (BSX) Reports Q3 Earnings

Before Wednesday's market open Boston Scientific (BSX) will post 2016 third quarter results.

Boston Scientific Launches Resolution 360™ Clip

Boston Scientific Launches Resolution 360™ Clip

Launch of Hemostasis Clip Advances Innovation within the Field of Endoscopy

Boston Scientific To Acquire EndoChoice

Boston Scientific To Acquire EndoChoice

Acquisition Will Expand Endoscopy Gastroenterology Portfolio

Jim Cramer's 'Mad Money' Recap: Here's What's Important Next Week

Jim Cramer's 'Mad Money' Recap: Here's What's Important Next Week

Cramer will be monitoring earnings and the Federal Reserve next week.

Jim Cramer's 'Mad Money' Recap: Strong Demand Keeps Market From Cratering

Jim Cramer's 'Mad Money' Recap: Strong Demand Keeps Market From Cratering

Demand is quite healthy and markets are not going into the abyss, Cramer says.

Cramer: This Is a Market of Stocks, not a Market of Markets

Cramer: This Is a Market of Stocks, not a Market of Markets

Pay attention to what companies are doing to improve themselves, not the hand-wringing from fund managers about Fed intervention.

Jim Cramer's Top Takeaways: Wells Fargo, Boston Scientific

Jim Cramer's Top Takeaways: Wells Fargo, Boston Scientific

Wells Fargo CEO John Stumpf apologizes to the bank's customers and Cramer says Boston Scientific is a stock to buy right now.